<DOC>
	<DOCNO>NCT00582504</DOCNO>
	<brief_summary>This study design determine safety immune response Venezuelan Equine Encephalomyelitis Vaccine , Live , Attenuated , Dried TC-83 , NDBR-102 ( TC-83 ) .</brief_summary>
	<brief_title>Safety Immunogenicity Study Venezuelan Equine Encephalomyelitis Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Encephalomyelitis</mesh_term>
	<mesh_term>Encephalomyelitis , Venezuelan Equine</mesh_term>
	<mesh_term>Encephalomyelitis , Equine</mesh_term>
	<criteria>At least 18 year old VEE PRNT80 &lt; 1:10 immunization . ( female ) Negative serum pregnancy test day vaccination . Not plan pregnancy 3 month . Actively enrol SIP At risk exposure virulent VEE virus ( uptodate risk assessment ) . Uptodate ( within 1 year ) physical examination/tests . Sign date approve informed consent . Willing return followup visit . Agree report adverse event ( AE ) 28 day vaccination . Over age 65 year . Clinically significant abnormal lab result include evidence Hepatitis C , Hepatitis B carrier state , elevate liver function test . History immunodeficiency current treatment immunosuppressive medication . ( female ) Currently breastfeed . Confirmed human immunodeficiency virus ( HIV ) titer . Family history ( first degree relative , elderly parent late onset ) diabetes , personal history gestational diabetes , confirm elevate fast serum glucose ( &gt; 125 mg/dL ) . Serious allergic reaction guinea pigs/guinea pig product . Any known allergy component vaccine . A medical condition judgment Principal Investigator ( PI ) would impact subject safety ( i.evaccination exposure another alphavirus ) . Administration vaccine within 28 day TC83 . Any unresolved AEs result previous immunization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Encephalitis , VEE</keyword>
</DOC>